Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Open Label & Double Blind Randomized Placebo-controlled Study to Assess the Feasibility of BGC101 (EnEPC) in the Treatment of Peripheral Arterial Disease (PAD) With Critical Limb Ischemia (CLI)

NCT02805023 is registered in ClinicalTrials.gov with BioGenCell Ltd. as lead sponsor.

NCT NCT02805023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02805023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Open Label & Double Blind Randomized Placebo-controlled Study to Assess the Feasibility of BGC101 (EnEPC) in the Treatment of Peripheral Arterial Disease (PAD) With Critical Limb Ischemia (CLI)
Lead sponsor
BioGenCell Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 30, 2016
Completion date
December 31, 2027
Enrollment
40 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic limb-threatening ischemia, peripheral arterial disease, peripheral vascular disease